Fresenius SE & Co. (OTCMKTS:FSNUY) Sees Significant Growth in Short Interest

Fresenius SE & Co. (OTCMKTS:FSNUY) was the recipient of a large growth in short interest in January. As of January 15th, there was short interest totaling 35,983 shares, a growth of 221.2% from the December 31st total of 11,203 shares. Currently, 0.0% of the shares of the stock are short sold. Based on an average daily volume of 179,753 shares, the short-interest ratio is currently 0.2 days. Based on an average daily volume of 179,753 shares, the short-interest ratio is currently 0.2 days. Currently, 0.0% of the shares of the stock are short sold.

Fresenius SE & Co. Price Performance

OTCMKTS FSNUY traded down $0.61 during trading hours on Wednesday, reaching $14.29. 3,090 shares of the stock traded hands, compared to its average volume of 83,199. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 0.99. The stock has a 50 day simple moving average of $14.13 and a two-hundred day simple moving average of $14.02. Fresenius SE & Co. has a 1 year low of $9.50 and a 1 year high of $33.93. The company has a market cap of $32.19 billion, a price-to-earnings ratio of 25.98 and a beta of 0.76.

Fresenius SE & Co. (OTCMKTS:FSNUY) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $0.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.21 by $0.02. The firm had revenue of $6.29 billion during the quarter, compared to analysts’ expectations of $6.38 billion. Fresenius SE & Co. had a return on equity of 9.72% and a net margin of 5.26%. On average, analysts predict that Fresenius SE & Co. will post 0.79 EPS for the current fiscal year.

Analyst Ratings Changes

FSNUY has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Fresenius SE & Co. in a research note on Monday, October 27th. Morgan Stanley reiterated an “overweight” rating on shares of Fresenius SE & Co. in a research report on Monday, December 15th. Two investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy”.

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments.